U.S. Markets closed

Cesca Therapeutics to Announce Financial Results for the First Quarter Ended March 31, 2018 and Host Conference Call on May 14

RANCHO CORDOVA, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the first quarter ended March 31, 2018 on Monday, May 14, 2018 after the close of trading. A conference call and webcast will follow at 4:30 p.m. EDT (1:30 p.m. PDT).

Participants may access the call by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing “Cesca.” To access a live webcast of the call, please visit: https://services.choruscall.com/links/kool180514.html.

A replay of the call will be available until June 14, 2018 and can be accessed by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and referencing access code 10119918.

About Cesca Therapeutics Inc.

Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing its automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market.

Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com 

Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com